ZyVersa Therapeutics Correlations
| ZVSA Stock | 4.28 0.03 0.70% |
The correlation of ZyVersa Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ZyVersa Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ZyVersa Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Average diversification
The correlation between ZyVersa Therapeutics and NYA is 0.11 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and NYA in the same portfolio, assuming nothing else is changed.
ZyVersa |
The ability to find closely correlated positions to ZyVersa Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ZyVersa Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ZyVersa Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ZyVersa Therapeutics to buy it.
Moving together with ZyVersa Stock
| 0.84 | DVAX | Dynavax Technologies | PairCorr |
| 0.85 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.76 | BMY | Bristol Myers Squibb | PairCorr |
| 0.71 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
| 0.76 | GILD | Gilead Sciences | PairCorr |
| 0.65 | IRWD | Ironwood Pharmaceuticals | PairCorr |
| 0.79 | ABBV | AbbVie Inc | PairCorr |
| 0.88 | ALKS | Alkermes Plc | PairCorr |
Moving against ZyVersa Stock
| 0.77 | BSGM | Biosig Technologies | PairCorr |
| 0.59 | AMRX | Amneal Pharmaceuticals | PairCorr |
| 0.59 | DCPH | Deciphera Pharmaceuticals | PairCorr |
| 0.55 | MRK | Merck Company Financial Report 6th of August 2024 | PairCorr |
| 0.51 | AMGN | Amgen Inc | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ZyVersa Stock performing well and ZyVersa Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ZyVersa Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MLGO | 26.40 | 10.70 | 1.62 | 1.46 | 4.93 | 11.64 | 852.61 | |||
| MSTSX | 0.46 | 0.01 | 0.00 | 0.05 | 0.67 | 0.90 | 3.08 | |||
| RRTLX | 0.26 | 0.01 | (0.03) | 0.05 | 0.22 | 0.59 | 1.36 | |||
| ANTMX | 0.62 | 0.04 | 0.07 | 0.08 | 0.62 | 1.23 | 3.55 | |||
| MLGF | 0.37 | 0.01 | (0.03) | (0.10) | 0.46 | 1.11 | 2.94 | |||
| GSFI | 2.98 | 1.54 | 0.00 | (1.72) | 0.00 | 0.00 | 100.00 | |||
| COLD | 1.28 | (0.18) | 0.00 | (0.14) | 0.00 | 2.54 | 8.95 | |||
| SEIC | 0.60 | (0.02) | (0.02) | 0.02 | 0.83 | 1.34 | 4.74 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in ZyVersa Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Risk-Return Analysis Now
Risk-Return AnalysisView associations between returns expected from investment and the risk you assume |
| All Next | Launch Module |
ZyVersa Therapeutics Corporate Management
Elected by the shareholders, the ZyVersa Therapeutics' board of directors comprises two types of representatives: ZyVersa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ZyVersa. The board's role is to monitor ZyVersa Therapeutics' management team and ensure that shareholders' interests are well served. ZyVersa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ZyVersa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| LaBella MS | Chief RD | Profile | |
| Melda Oconnell | Senior Development | Profile | |
| Pablo MD | Chief Board | Profile | |
| MD FACC | Senior Officer | Profile | |
| Karen Cashmere | Chief Officer | Profile |
Already Invested in ZyVersa Therapeutics?
The danger of trading ZyVersa Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ZyVersa Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ZyVersa Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ZyVersa Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for ZyVersa Stock analysis
When running ZyVersa Therapeutics' price analysis, check to measure ZyVersa Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ZyVersa Therapeutics is operating at the current time. Most of ZyVersa Therapeutics' value examination focuses on studying past and present price action to predict the probability of ZyVersa Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ZyVersa Therapeutics' price. Additionally, you may evaluate how the addition of ZyVersa Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |
Is ZyVersa Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (958.35) | Return On Assets (0.12) | Return On Equity (1.80) |
The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.